Filing Flows › Boston Scientific (BSX) › Q2 2026 › vs Q2 2025
Boston Scientific (BSX) Q2 2026 vs Q2 2025 (year over year)
Boston Scientific's revenue rose $381M (+8%) from $5.1B in Q2 2025 to $5.4B in Q2 2026. The biggest changes: Interventional Cardiology & Vascular Therapies +$155M (+13%); Electrophysiology +$76.0M (+9%); Endoscopy +$56.0M (+8%). Gross margin 70.7% against 67.7% (+3.1 pts).
Boston Scientific, Q2 2026: revenue $5.4B (+8% year over year), operating margin 21.6%, net earnings $905M, operating cash flow $1.5B. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.7% | 67.7% | +3.1 pts |
| Operating margin | 21.6% | 16.2% | +5.5 pts |
| Net margin | 16.6% | 15.7% | +0.9 pts |
| Free cash flow margin | 23.5% | 22.3% | +1.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.3B | $1.2B | $155M | +13% |
| Electrophysiology | $916M | $840M | $76.0M | +9% |
| Endoscopy | $793M | $737M | $56.0M | +8% |
| Urology | $684M | $676M | $8.0M | +1% |
| Cardiac Rhythm Management | $585M | $590M | −$5.0M | -0.8% |
| Watchman | $507M | $486M | $21.0M | +4% |
| Neuromodulation | $341M | $303M | $38.0M | +13% |
| Interventional Oncology & Embolization | $283M | $251M | $32.0M | +13% |
| Revenue | $5.4B | $5.1B | $381M | +8% |
| Gross profit | $3.8B | $3.4B | $424M | +12% |
| Cost of revenue | $1.6B | $1.6B | −$43.0M | -3% |
| Operating profit | $1.2B | $819M | $359M | +44% |
| Operating expenses | $2.7B | $2.6B | $65.0M | +2% |
| Pre-tax earnings | $1.1B | $941M | $119M | +13% |
| Other expense, net | $118M | −$122M | $240M | — |
| Research & development | $554M | $526M | $28.0M | +5% |
| SG&A | $1.8B | $1.7B | $87.0M | +5% |
| Other operating costs | $313M | $363M | −$50.0M | -14% |
| Net earnings | $905M | $795M | $110M | +14% |
| Income tax | $155M | $146M | $9.0M | +6% |
| Depreciation & amortization | $355M | $336M | $19.0M | +6% |
| Share-based compensation | $87.0M | $75.0M | $12.0M | +16% |
| Working capital & other | $127M | $80.0M | $47.0M | +59% |
| Operating cash flow | $1.5B | $1.3B | $188M | +15% |
| Free cash flow (OCF − capex) | $1.3B | $1.1B | $150M | +13% |
| Capital expenditures | $195M | $157M | $38.0M | +24% |
Questions
How much did Boston Scientific's revenue grow year over year in Q2 2026?
Boston Scientific's revenue rose $381M (+8%) from $5.1B in Q2 2025 to $5.4B in Q2 2026.
What drove Boston Scientific's revenue change in Q2 2026?
Interventional Cardiology & Vascular Therapies +$155M (+13%); Electrophysiology +$76.0M (+9%); Endoscopy +$56.0M (+8%).